Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 13/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892222 | 1.00 | MRGPRX4 (0.48) | MRGPRX4DRD4TSHRTP53MAPT | |
| SCHEMBL10407011 | 0.85 | ALDH1A1 (0.59) | DRD4TSHRTP53MAPTHPGD | |
| SCHEMBL909426 | 0.82 | TSHR (0.47) | DRD4TSHRTP53MAPTHPGD | |
| SCHEMBL909427 | 0.82 | TSHR (0.47) | DRD4TSHRTP53MAPTHPGD | |
| SCHEMBL909731 | 0.82 | TSHR (0.47) | DRD4TSHRTP53MAPTHPGD | |
| SCHEMBL3142607 | 0.82 | ALDH1A1 (0.48) | DRD4TSHRTP53MAPTHPGD | |
| SCHEMBL29847383 | 0.81 | TSHR (0.45) | DRD4TSHRTP53MAPTHPGD | |
| SCHEMBL21296293 | 0.80 | ALDH1A1 (0.50) | DRD4TSHRTP53MEN1KMT2A | |
| SCHEMBL7962015 | 0.80 | ALDH1A1 (0.49) | DRD4TSHRTP53HPGDALDH1A1 | |
| SCHEMBL7962011 | 0.80 | ALDH1A1 (0.49) | DRD4TSHRTP53HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590929-A1 | ARYLOXY-ALKYLENE SUBSTITUTED HYDROXYPHENYL HEXYNOIC ACIDS, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI (FR) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012010413-A1 | ARYLOXY-ALKYLENE SUBSTITUTED HYDROXYPHENYL HEXYNOIC ACIDS, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI (FR) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010413-A1 | ARYLOXY-ALKYLENE SUBSTITUTED HYDROXYPHENYL HEXYNOIC ACIDS, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI (FR) | 2012-01-26 | — | — | WO | disclosed |
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | HCAR1, HCAR3, CYP2C9 | MRGPRX4 417/4885DRD4 289/4885TSHR 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.